Background Until now, only imatinib and sunitinib have proven clinical benefi t in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess effi cacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.
Introduction
Gastrointestinal stromal tumours (GIST) are the most common sarcomas arising in the gastrointestinal tract. Worldwide, the annual incidence of GIST is about 10 cases per million people, 1 corresponding to at least 8000 new cases per year in Europe. Early-stage disease can be surgically resected, but more than 40% of cases recur and metastasise. 2 Cytotoxic chemotherapy, although active in other subtypes of sarcomas, is ineff ective in metastatic GIST. 3, 4 Elucidation of GIST molecular pathophysiology as a mutation-driven cancer has facilitated the development of targeted kinase-inhibitor therapies that have revolutionised treatment options and clinical outcomes for this malignancy. 5 About 85% of GIST are caused by gain-of-function mutations in the proto-oncogene KIT, 6 which encodes a tyrosine-kinase receptor. These mutations result in constitutive ligand-independent activation of KIT intracellular signalling. 1, 7, 8 Roughly 8% of metastatic GIST are associated with gain-of-function mutations in the structurally similar tyrosine-kinase receptor gene PDGFRA, encoding the platelet-derived growth factor receptor α. 6, 8, 9 Other rare subtypes of GIST exist that harbour no mutations in KIT or PDGFRA, but are probably driven by other mutations in genes such as BRAF, NF1, or those encoding subunits of the succinate dehydrogenase (SDH) complex.
Imatinib mesylate, a selective tyrosine-kinase inhibitor of KIT, PDGFRA, and ABL, signifi cantly improves clinical outcomes in GIST both as therapy for advanced metastatic disease and in the postsurgical adjuvant setting. [10] [11] [12] [13] However, imatinib therapy is limited by primary resistance to the drug in about 15% of patients, 5, [14] [15] [16] and more than 80% of patients eventually develop disease progression driven by secondary resistance mutations located in KIT exons. [16] [17] [18] [19] [20] The fi rst drug shown defi nitively to provide clinical benefi t in GIST after resistance to imatinib was sunitinib malate, which has more potent activity against the wild-type KIT kinase than the fi rst-line treatment, imatinib, and also inhibits several other signalling pathways related to tyrosine-kinase receptors, including the vascular endothelial growth factor receptors (VEGFR1 [also known as FLT1], VEGFR2 [KDR] , and VEGFR3 [FLT4]), Fms-like tyrosine kinase-3 (FLT3), and the receptor encoded by the proto-oncogene RET. [21] [22] [23] [24] [25] A randomised, placebo-controlled phase 3 trial assessing sunitinib in imatinib-resistant patients showed a signifi cant improvement in median time to tumour progression for sunitinib compared with placebo (all patients also received best supportive care). 26 However, clinical progression and drug resistance to sunitinib subsequently evolve, generally within 1 year of treatment, and up to now, no other eff ective therapy has been developed for tyrosine-kinase inhibitor-resistant GIST. Structural biology studies have explained that the smaller sunitinib molecule shows activity in patients who are imatinib-resistant because sunitinib is able to avoid steric hindrance by gatekeeper mutations that block entrance of the larger imatinib molecule to the ATP-binding pocket of the KIT protein. 27 Regorafenib is a novel, oral multikinase inhibitor that blocks the activity of several protein kinases, including those involved in the regulation of tumour angiogenesis (VEGFR1-3 and TEK), oncogenesis (KIT, RET, RAF1, BRAF, and BRAF V600E ), and the tumour micro environment (PDGFR and FGFR). 28 In preclinical studies, regorafenib showed antitumour activity against human GIST and other tumour models. 28 After the phase 1 study that defi ned the safety, tolerability, and recommended dose of regorafenib in unselected patients with solid tumours, 29 a phase 2 multicentre trial was designed and done under independent academic sponsorship to assess regorafenib in patients with GIST with metastatic disease, after failure of at least previous imatinib and sunitinib. 30 In that phase 2 study, regorafenib showed activity against tyrosinekinase inhibitor-resistant GIST, including some partial responses, a high occurrence of durable stable disease, and median progression-free survival (PFS) of 10 months, along with the expected incidence of grade 3 toxic eff ects of hypertension and hand-foot skin reaction. 30 On the basis of these data and the preclinical rationale of targeting the pathogenic mutant kinases with a structurally distinct small-molecule inhibitor, we did this phase 3 trial (GIST-regorafenib in progressive disease [GRID] ) to assess effi cacy and safety of regorafenib in patients with metastatic or unresectable GIST, progressing after failure of at least previous imatinib and sunitinib. We report the effi cacy and safety results of this trial; qualityof-life data were collected and will be reported separately and a fi nal analysis of overall survival will be done when approximately 136 events have been recorded.
Methods

Study design and participants
We did this randomised, placebo-controlled, multicentre, phase 3 trial at 57 hospital sites in 17 countries (Austria, Belgium, Canada, China, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, UK, and USA).
Eligibility criteria included histologically confi rmed, metastatic or unresectable GIST, with failure of at least previous imatinib (defi ned as either disease progression or intolerance) and previous sunitinib (defi ned solely as progression to decrease heterogeneity, since the definition of intolerance is more variable with this agent than with imatinib). Patients could have received other systemic therapies, including investigational agents, except any VEGFR inhibitors other than sunitinib. Additional inclusion criteria included: at least one measurable lesion with CT or MRI; resolution of all toxic eff ects of previous therapy to grade 1 or lower; adequate haematological, hepatic, cardiac, and renal function; and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The appendix provides additional details of inclusion and exclusion criteria.
The study protocol was approved by the institutional review board of each participating institution and complied with the Declaration of Helsinki, existing good clinical practice guidelines, and local laws and regula tions. An independent data monitoring committee, of three oncologists and a statistician, ensured the overall integrity of the trial and safety of participants. All participants provided written informed consent before enrolment.
Randomisation and masking
Patients were randomly assigned in a 2:1 ratio to regorafenib or placebo with a computer-generated randomisation list prepared by the study sponsor (preallocated block design, block size 12). Investigators received the randomisation number for each participant through an interactive voice response system, which was also used to manage study drug supply. Randomisation was stratifi ed by treatment line (failure of previous imatinib and sunitinib [true third-line] vs failure of previous imatinib, sunitinib, and other GIST therapies) and geographical region (Asia vs rest of world).
Randomisation was masked so that neither the patient, nor the investigator, nor the sponsor knew which agent was being administered. To maintain concealment, study medication was labelled with a unique drug pack number preprinted on each bottle, which was assigned to the patient through the interactive voice response system. Unmasking for individual patients could occur via the voice response system for emergencies; serious adverse events did not necessarily precipitate immediate unmasking.
Procedures
Enrolled patients received either oral regorafenib 160 mg once daily or matching placebo, for the fi rst 3 weeks of each 4 week cycle. All patients also received best supportive care (defi ned as any method to preserve the comfort and dignity of the patient, excluding diseasespecifi c antineoplastic therapy, such as tyrosine-kinase therapy other than study drug, chemotherapy, radiation therapy, or surgical intervention). Masked study drug administration was continued until disease progression, occurrence of unacceptable toxic eff ects, or withdrawal of the patient from the study.
In the event of centrally assessed tumour progression, treatment assignment could be unmasked. Patients originally assigned to the placebo group were off ered the option to crossover to receive open-label regorafenib, and patients originally assigned to the regorafenib group could continue to receive open-label regorafenib, both at the discretion of the investigator. Throughout both the masked and open-label phases of the trial, the dose of study drug could be delayed or reduced according to a prespecifi ed schedule in the case of unacceptable toxic eff ects (appendix).
Tumour assessments were made at baseline, then every 4 weeks for the fi rst 3 months, every 6 weeks for the next 3 months, and subsequently every 8 weeks until the end of study drug administration. Intervening tumour assessments could be made more frequently when clinically indicated. In addition to central review, an investigator assessment was also made at each evaluation. During the open-label period, only investigator assessments were made.
We assessed safety and tolerability by analysis of adverse events, physical examinations, vital signs, ECOG performance status, and laboratory assessments, on days 1 and 15 of each treatment cycle for the fi rst six cycles. Cardiac function was assessed with 12-lead electrocardiogram at screening, day 1 of the fi rst two treatment cycles (and subsequent cycles at the discretion of the investigator), and at treatment end. Investigators rated severity of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
The primary endpoint was PFS per modifi ed Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, assessed by central radiology reviewers who were masked to assignment and data from patients. The prospectively defi ned RECIST modifi cations, which were unique to this study and developed to apply specifi cally to GIST, were the following criteria: no lymph nodes were chosen as target lesions-enlarged lymph nodes were followed up as non-target lesions; no bone lesions were chosen as target lesions; and PET was not acceptable for radiological assessment. Additionally a progressively growing new tumour nodule within a pre-existing tumour mass had to meet the following criteria to be regarded as unequivocal evidence of progression according to our modifi cation to RECIST 1.1: the lesion was at least 2 cm in size and defi nitely a new active GIST lesion (eg, enhanced with contrast or other criteria to rule out artifact); or the lesion had to be expanding on at least two sequential imaging studies. The masked central radiology review was done according to a prospectively agreed central imaging charter and undertaken by an external imaging contract research organisation. Two readers reviewed the images. Adjudication by another radiology reviewer was used when only one reader assessed a progression or when the date of progression was discordant between the two independent readers. Secondary endpoints included overall survival, time to progression, objective response rate, and disease control rate (defi ned as rate of complete response or partial response plus stable disease lasting for at least 12 weeks), safety, and tolerability. Exploratory endpoints (not reported here) were health-related quality of life, pharmaco kinetics, secondary PFS during open label treatment, and biomarker assessment, including tumour genotype for mutational status of target oncogene.
Statistical analysis
With 199 patients randomised, assuming a target treatment eff ect of 100% improvement in PFS, a randomisation ratio of 2:1 (regorafenib to placebo), a one-sided alpha of 0·01, and a power of 0·94, 144 events were needed for the fi nal PFS analysis. A preplanned interim analysis of overall survival was done at the time of the fi nal PFS analysis.
We did statistical analyses with SAS (version 9.1 or higher). Effi cacy analyses were by intention to treat. Safety analyses included all patients who received at least one dose of study drug. We calculated PFS and overall survival estimates with the Kaplan-Meier method. We derived hazard ratios (HRs) and 95% CIs from a Cox proportional hazard model and p values with the stratifi ed log-rank test. Overall response rate and disease control rate were analysed with the Cochran-MantelHaenszel test. This trial is registered with ClinicalTrials. gov, number NCT01271712.
Role of the funding source
The study sponsor provided regorafenib and matching placebo, and collaborated with the principal investigator (GDD) and an international steering committee of academic investigators on protocol design, data collection and interpretation, and preparation of this report. All logistical study operations were managed by the sponsor. Data were collected by the sponsor and analysed by the principal investigator, steering committee, and sponsor. All authors had full access to all data and vouch for the accuracy and completeness of the data presentation and analysis. The authors had fi nal responsibility to submit for publication.
Results
Between Jan 04, and Aug 18, 2011, 240 patients were screened and 199 patients were randomised to receive regorafenib (n=133) or placebo (n=66; fi gure 1). One patient randomised to the regorafenib group died before receiving study treatment. Baseline characteristics and previous treatments were much the same between the two groups, although by chance a higher proportion of patients in the placebo group had received imatinib therapy for more than 18 months than in the regorafenib group (table 1); 193 patients (97%) had previous disease progression while on both imatinib and sunitinib, with only six patients (3%) entered with a history of intolerance to imatinib. Notably, 86 patients (43%) had received three or more previous lines of anticancer therapy for GIST.
Analysis was done when the predetermined criteria of 144 PFS events was reached: 81 events among the 133 patients (61%) in the regorafenib group and 63 events among the 66 patients (95%) in the placebo group. During the double-blind period, 38 patients (29%) in the regorafenib group and seven (11%) patients in the placebo group discontinued study treatment (appendix). The most common reason for termination of study treatment was radiologically confi rmed disease progression.
At the data cutoff (Jan 26, 2012), 53 (40%) of the 133 patients in the regorafenib group and three (5%) of the 66 patients in the placebo group were still receiving double-blind treatment (fi gure 1). A further 41 patients (31%) in the regorafenib group continued to receive open-label regorafenib after disease progression, and 24 (18%) of the 41 patients were still receiving regorafenib at the time of analysis. In the placebo group, 56 patients (85%) crossed over to receive open-label regorafenib after progression, and 33 (50%) were still receiving treatment at data cutoff (fi gure 1, appendix). The appendix includes a summary of post-study treatments. During the double-blind period, patients who were assigned to receive regorafenib had a median treatment duration of 22·9 weeks (IQR 9·3-28·6), with a mean of 20·2 weeks (SD 11·6), and patients who were assigned to receive placebo had a median treatment duration of 7·0 weeks (IQR 5·1-11·3), with a mean of 9·1 weeks (SD 5·9). The median daily dose during the double-blind treatment period was 146·8 mg (IQR 125·1-160·0) for regorafenib-treated patients (mean 139·8 mg, SD 22·9) and 160 mg (IQR 160·0-160·0) for placebo recipients (mean 159·5 mg, SD 3·0). In the regorafenib group, patients received 78·0% of the planned dose; in the placebo group, patients received 83·8% of the planned dose.
Median PFS was 4·8 months (IQR 1·4-9·2) in the regorafenib group and 0·9 months (0·9-1·8) in the placebo group, according to blinded central review (HR 0·27, 95% CI 0·19-0·39; p<0·0001; fi gure 2A), meeting the primary endpoint of the study. PFS at 3 and 6 months was 60% (95% CI 51-68) and 38% (29-48), respectively, for regorafenib, and 11% (3-18) and 0% (0-0), respectively, for placebo. Investigator assessment showed a median PFS of 7·4 months (IQR 2·7-not calculable) in the regorafenib group and 1·7 months (0·9-2·7) in the placebo group (HR 0·22, 95% CI 0·14-0·35; p<0·0001; appendix). Median PFS for the 56 patients in the placebo group who crossed over to open-label regorafenib after progression was 5·0 months (IQR 3·1-8·7) per investi gator assessment). We noted no signifi cant diff erence in overall survival between the regorafenib and placebo groups (29 [22%] events in the regorafenib group vs 17 [26%] events in the placebo group; HR 0·77, 95% CI 0·42-1·41; p=0·199; fi gure 2B).
We analysed the eff ect of baseline factors on treatment eff ect with a Cox proportional hazard model (fi gure 3). The benefi ts of regorafenib on centrally assessed PFS were identifi ed across all subgroups, except for the small subset of patients with duration of imatinib treatment of less than 6 months. We identifi ed much the same benefi ts of regorafenib in patients whose tumours harboured the two most com mon primary KIT mutations (exon 11 mutation, n=51, HR 0·212, 95% CI 0·098-0·458; exon 9 mutation, n=15, 0·239, 0·065-0·876).
No patients in either group had a complete response, whereas six of the 133 patients in the regorafenib group and one of the 66 patients in the placebo group had a partial response, giving overall response rates of 4·5% for regorafenib and 1·5% for placebo. The occurrence of stable disease as best response (occurring at any time and for any duration) was 71·4% (95 of 133 patients) in the regorafenib group and 33·3% (22 of 66 patients) in the placebo group. The more clinically meaningful disease control rate was 52·6% (70 of 133 patients) for regorafenib and 9·1% (six of 66 patients) for placebo (95% CI -54·72 to -32·49; p<0·0001).
D uring the double-blind period, all 132 assessable patients in the regorafenib group and 61 (92%) of the 66 patients in the placebo group had adverse events. Drug-related adverse events were reported in 130 (98%) patients in the regorafenib group and 45 (68%) patients in the placebo group (table 2). The most common adverse event of any grade was hand-foot skin reaction, which occurred in 74 (56%) patients in the regorafenib group and nine (14%) patients in the placebo group. Drug-related adverse events of grade 3 or higher were reported in 81 (61%) patients assigned regorafenib and nine (14%) patients assigned placebo. The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132 patients, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%). Grade 5 adverse events were reported in seven (5%) patients in the regorafenib group and three (5%) patients in the placebo group. In three patients, the 
Discussion
When added to best supportive care, regorafenib signifi cantly improves PFS in a population of patients with GIST with progressive disease after failure of all approved previous therapies, compared with matching placebo. Median PFS with regorafenib was more than fi ve times that with placebo, reducing the risk of progression or death by 73%. Although the regorafenib group might have included patients with more indolent disease, we believe that the robust results argue against any such confounding eff ect of disease-specifi c variables and instead are evidence of regorafenib activity to arrest disease progression. 56 (85%) of the 66 patients assigned placebo accessed regorafenib after disease progression, which could have confounded any potential diff erence in overall survival between groups.
GIST is the most common sarcoma subtype. 31 Elucidation of GIST molecular pathogenesis has allowed rational translation of basic science into clinical therapies targeting the root cause of the disease, usually KIT or PDGFRA mutations. Inhibition of these driver mutations has improved disease control, leading to increased survival of patients with GIST. 10, 11, 26 Despite these advances, only two tyrosine-kinase inhibitors, imatinib and sunitinib, have been shown to be clinically benefi cial to patients with GIST, and resistance to these agents eventually leads to disease progression and death in most patients with advanced GIST. Several other structurally distinct inhibitors of KIT and PDGFRA kinases have been developed, but, despite promise in control of tyrosine-kinase inhibitor-resistant disease in early phase trials, until now, none has shown benefi t in prospective phase 3 trials (panel). 32, 33 As with other eff ective kinase inhibitors in tyrosinekinase inhibitor-resistant disease, in the present study regorafenib did not induce high rates of objective tumour response per modifi ed RECIST. 26 However, disease control rate was higher in patients in the regorafenib group than in those in the placebo group, suggesting that regorafenib was associated with clinically Data are n (%). *Excluding one patient who did not receive study treatment. Table 2 : Drug-related adverse events in ≥10% of patients during double-blind treatment period meaning ful tumour control in patients with advanced GIST after failure of all other approved tyrosine-kinase inhibitor therapies. Effi cacy analysis in prespecifi ed subgroups showed robustness in the benefi t of regorafenib compared with placebo in nearly all subgroups. In particular, regorafenib had much the same benefi t compared with placebo for patients receiving treatment either as third-line therapy or as fourth or later line of therapy. This result suggests that regorafenib can achieve therapeutic benefi t independent of previous treatment regimens. A possible explanation is that regorafenib targets several pathways contributing to GIST pathogenesis, which might block resistance mechanisms. 28 The safety profi le of regorafenib in this study was much the same as that identifi ed in previous clinical trials. 29, 30 Regorafenib dosing was reasonably well tolerated within the predefi ned rules for dose modification (dose delays or reductions, with an option to dose escalate again on the basis of tolerability; appendix). Adverse events leading to permanent treatment discontinuation were much the same in the two study groups. The most common drug-related adverse events in the regorafenib group were hyper tension, hand-foot skin reaction, and diarrhoea. Drug-related grade 3 or higher hypertension was reported in 31 (23%) of 132 patients assigned regorafenib and, similarly to other therapies targeting the VEGF/VEGFR pathway, 26, 32 is probably related to antiangiogenic eff ects. This adverse event could be managed with dose modifi cation and appropriate anti hypertensive inter vention. Drug-related hand-foot skin reaction is also commonly associated with other multi targeted kinase inhibitors. 26, 32 In GRID, this adverse event was generally manageable with dose modifi cations and proper care of the aff ected skin area.
This rigorously conducted large-scale international collaboration provides robust evidence that regorafenib can control progressive GIST after failure of other approved kinase inhibitors, and this benefi t is much the same across many characteristics of patients, including ethnic group, age, performance status, and commonly mutated forms of the oncogenic KIT driver mutations. Further work is underway to understand more fully the activity of regorafenib among rare mutational subtypes of GIST besides these common KIT mutant subtypes.
Future studies of regorafenib in GIST will investigate further the molecular mechanisms by which the treatment can induce disease control after failure of both imatinib and sunitinib. Specifi cally, tumour genotypes will be studied as predictive tumour biomarkers in an eff ort to correlate molecular subtypes of the disease with regorafenib activity. Increased understanding of the key pathways involved in successful treatment of GIST refractory to both imatinib and sunitinib could provide new insight into mechanisms of resistance to molecularly targeted therapies. 
Interpretation
Our work is a translation of the evolving scientifi c understanding of aberrant intracellular signalling in GIST. Since 1998, researchers have recognised that most GIST lesions have constitutively activated signalling through either the KIT or PDGRFA kinase pathways. The existing treatment options for patients with metastatic GIST are limited to only two kinaseinhibiting drugs, imatinib and sunitinib. Once a patient has disease progressing despite therapy with these two agents, no therapeutic options have shown effi cacy. Our translational science has previously suggested that structurally distinct kinase-inhibiting agents with novel activities could overcome resistance to imatinib and sunitinib, and thereby off er clinical benefi ts to patients with this life-threatening disease. After promising clinical phase 2 evidence of antitumour activity of regorafenib in pretreated patients, this international, randomised, placebo-controlled phase 3 trial shows that oral regorafenib can indeed provide a signifi cant progression-free survival benefi t compared with placebo in patients with pretreated, progressive metastatic GIST. The study confi rms that drug-resistant GIST remains an oncogene-addicted disease that can be therapeutically targeted by new structural inhibitory attacks on the pathogenic mutated kinase. As far as we are aware, this is the fi rst clinical trial to show benefi t from a kinase inhibitor after objective resistance to two previous kinase-inhibiting therapies in a disease driven by an oncogenic kinase mechanism.
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